Akèy › Kansè (tout kalite) › Florid › Tampa
Etid klinik pou Kansè (tout kalite) nan Tampa, FL
39 etid pou Kansè (tout kalite) ap chèche patisipan nan sit nan ak bò kote Tampa (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer
Ap rekriteFaz 2/3
- Moffitt Cancer Center /ID# 276785, Tampa
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
Ap rekriteFaz 1
- Moffit Cancer Center, Tampa
A Study to Evaluate Adverse Events, Change in Disease Activity, Tolerability, and How Intravenous ABBV-438 Moves Through the Body in Adult Participants With Multiple Myeloma (MM)
Ap rekriteFaz 1
- Moffitt Cancer Center /ID# 279068, Tampa
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto
Ap rekriteEtid obsèvasyon
- H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc., Tampa
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
Ap rekriteEtid obsèvasyon
- Moffitt Cancer Center, Tampa
A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms
Ap rekriteFaz 1
- Moffit Cancer center, Tampa
A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer
Ap rekriteFaz 3
- Moffitt Cancer Center /ID# 279732, Tampa
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
Ap rekriteFaz 1/2
- Moffitt Cancer Center and Research Institute, Tampa
Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)
Ap rekriteEtid obsèvasyon
- Moffitt Cancer Center, Tampa
Prospective Study to Assess a Diagnostic Aid for Cancer
Ap rekriteEtid obsèvasyon
- Avita Clinical Research, Tampa
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Ap rekriteFaz 2/3
- USF Health Morsani Center for Advanced Healthcare, Tampa
- H. Lee Moffitt Cancer Center and Research Institute University of South Florida, Tampa
RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses
Ap rekriteFaz 2
- University of South Florida, Department of Psychiatry and Behavioral Neuroscience, Tampa
A Study to Investigate Safety and Effectiveness of Tacabrutideg (BGB-16673) in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
Working Through Outreach, Navigation and Digital Enabled Referral and Recruitment Strategies (ACT WONDER²S)
Ap rekriteVolontè an sante akeyi
- Moffitt Cancer Center, Tampa
A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
A Study to Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
Project: Every Child for Younger Patients With Cancer
Ap rekriteEtid obsèvasyon
- Tampa General Hospital, Tampa
- Saint Joseph's Hospital/Children's Hospital-Tampa, Tampa
Abatacept in Immune Checkpoint Inhibitor Myocarditis
Ap rekriteFaz 3
- Moffitt Cancer Center, Tampa
Expanding the Support of Family Caregivers of Diverse Patients With Cancer and Diabetes
Ap rekriteVolontè an sante akeyi
- Moffitt Cancer Center, Tampa
A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations
Ap rekriteFaz 1/2
- Moffitt Cancer Center /ID# 272628, Tampa
A Study to Assess Adverse Events and Change in Disease Activity in Adult Participants Receiving Intravenously Infused Telisotuzumab Adizutecan Alone or With Standard of Care in Participants With Post Adjuvant Circulating Tumor DNA Positive Colorectal Cancer and No Radiographic Evidence of Disease
Ap rekriteFaz 2
- Moffitt Cancer Center /ID# 274372, Tampa
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Ap rekriteFaz 2
- Moffitt Cancer Center, Tampa
Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC
Ap rekriteFaz 1/2
- H Lee Moffitt Cancer Center and Research Institute, Tampa
A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Ap rekriteFaz 1/2
- Moffitt Cancer Center and Research Institute, Tampa
Galleri® in the Medicare Population.
Ap rekriteVolontè an sante akeyi
- USF Morsani Center for Advanced Healthcare, Tampa
A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-130037 in Participants With Advanced Solid Tumors
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Ap rekriteFaz 2
- H. Lee Moffitt Cancer Center and Research Institute, Tampa
- Moffitt Cancer Center, Tampa
A Study to Evaluate the Efficacy and Safety of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC
Ap rekriteFaz 2
- Moffitt Cancer Center, Tampa
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Ap rekriteFaz 1
- Moffitt Cancer Center, Tampa
Beat Childhood Cancer Specimen Banking and Data Registry
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- St. Joseph's Children's Hospital, Tampa
Caris Biorepository Research Protocol
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- The University of South Florida, Tampa
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Tampa
BMT-CARE: Psychosocial Intervention for Transplant Caregivers
Ap rekrite
- Moffitt Cancer Center, Tampa
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
Ap rekrite
- Moffitt Cancer Center - McKinley Campus, Tampa
- Moffitt Cancer Center, Magnolia Campus, Tampa
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Ap rekriteFaz 1/2
- Moffitt Cancer Center, Tampa
Etid Kansè (tout kalite) nan lòt vil
- Houston, TX121 etid
- New York City, NY110 etid
- Boston, MA86 etid
- Los Angeles, CA73 etid
- Nashville, TN65 etid
- Philadelphia, PA59 etid
- Durham, NC58 etid
- Washington, DC58 etid
- Chicago, IL51 etid
- Seattle, WA49 etid
- Atlanta, GA49 etid
- Arlington, VA48 etid
Lòt etid nan Tampa
- Kansè Poumon ki pa ti selil51 etid
- Kansè nan tete43 etid
- Kansè kolorektal33 etid
- Kansè Metastatik29 etid
- Kansè poumon29 etid
- Leksemi mieloïd egi29 etid
- Kansè pankreyas26 etid
- Kansè ovè21 etid
- Sendwòm myelodisplastik19 etid
- Melanom19 etid
- Ensifizyans kadyak18 etid
- Kansè pwostat18 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.